Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
TEGSEDI is the first antisense medicine available to patients in Spain for at-home subcutaneous injection Approval Issued by Ministry of
14 Maggio 2020
